Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations

Nine different human melanomas and 16 clones, isolated from 2 of them, were characterized for susceptibility to rIL1‐β, rIL4‐, rTNF‐α‐ and rIFN‐γ‐mediated effects on proliferation and surface expression of class‐II HLA (DR and DP), ICAM‐1 and LFA‐3 molecules and of 3 tumor‐associated antigens (recognized by MAb 763.74T, 149.53 and R24). In spite of marked inter‐ and intra‐tumor heterogeneity for susceptibility to the effects of each cytokine, the most frequent upregulation was induced on the HLA class‐II antigens by rIFN‐γ and on adhesion molecules by rIFN‐γ, rTNF‐α and rlL1‐β, while tumor‐associated antigens were often down‐modulated by rIFN‐γ. Tumor heterogeneity was also evident on tumorcell proliferation with an apparent hierarchy in the frequency and extent of inhibitory effects: rIFN‐γ >rTNF‐α >rIL1‐β =rIL4. Combinations of 2 cytokines resulted in rare and limited changes in the antigenic profile in comparison to the effects seen with single factors, while the combination of rTNF‐α and rIFN‐γ resulted in significant synergistic antiproliferative effects on most tumor cells and clones. Taken together, these results indicate that single cytokines can profoundly affect the antigenic profile of melanoma cells, while strong tumor‐growth inhibition is often achieved by combinations of 2 cytokines acting in synergism.

[1]  J. Y. Tsao,et al.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF , 1988, Cancer Immunology, Immunotherapy.

[2]  D. Guerry,et al.  Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. , 1989, Journal of immunology.

[3]  J. Trowsdale,et al.  Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells , 1989, Nature.

[4]  R. Mirsky,et al.  Schwann cells co‐cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon‐γ pretreatment: synergistic effects of interferon‐γ and tumor necrosis factor on MHC class II induction , 1989, European journal of immunology.

[5]  N. de Tribolet,et al.  Effects of recombinant human tumor necrosis factor‐α on the surface phenotype and the growth of human malignant glioma cell lines , 1988 .

[6]  R. Rothlein,et al.  Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. , 1988, Journal of immunology.

[7]  W. Fiers,et al.  Autocrine secretion of tumor necrosis factor under the influence of interferon-gamma amplifies HLA-DR gene induction in human monocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Figdor,et al.  IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. , 1988, Journal of immunology.

[9]  J. Banchereau,et al.  Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma. , 1988, Journal of immunology.

[10]  T. Springer,et al.  ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells , 1988, Nature.

[11]  G. Sozzi,et al.  Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. , 1987, Journal of immunology.

[12]  H. Holtmann,et al.  Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. , 1987, Journal of immunology.

[13]  R. Saxton,et al.  Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. , 1987, Cancer research.

[14]  W. Paul,et al.  B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. , 1987, Journal of immunology.

[15]  P. Scheurich,et al.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. , 1987, Journal of immunology.

[16]  Y. Ichinose,et al.  Cytostatic and cytolytic effects of human recombinant tumor necrosis factor on human renal cell carcinoma cell lines derived from a single surgical specimen. , 1987, Journal of immunology.

[17]  P. Scheurich,et al.  Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. , 1987, Journal of immunology.

[18]  V. Ruggiero,et al.  Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. , 1987, Journal of immunology.

[19]  W. Paul,et al.  Regulation of class II gene expression: analysis in B cell stimulatory factor 1-inducible murine pre-B cell lines. , 1986, Journal of immunology.

[20]  A. Anichini,et al.  Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ , 1986, International journal of cancer.

[21]  I. Fidler,et al.  Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. , 1986, Journal of immunology.

[22]  J. Tavernier,et al.  Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. , 1986, Journal of immunology.

[23]  K. Resch,et al.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. , 1986, Journal of immunology.

[24]  W. Fiers,et al.  Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Taramelli,et al.  Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. , 1986, Cancer research.

[26]  B. Aggarwal,et al.  Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.

[27]  B. Aggarwal,et al.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.

[28]  A. Aguzzi,et al.  Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. , 1985, Journal of immunology.

[29]  J. Kirkwood,et al.  Interferons in the treatment of human cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Ferrone,et al.  Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. , 1982, Clinical chemistry.

[31]  J. Strominger,et al.  Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Accolla,et al.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Old,et al.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.